MedTrace Logo

Selective β2-AR Antagonism in Asthma

NCT07272135 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-12-09

No results posted yet for this study

Summary

The objectives are to assess the safety, tolerability and effect on the airways of TR4 in patients with mild-to-moderate asthma. The Phase 1 trial is randomised, double-blind, placebo-controlled, and ascending-dose in design.

Conditions

Interventions

OTHER

Placebo

Placebo capsules will contain start in opaque capsules.

DRUG

TR4

TR4 is a selective beta-2-adrenoceptor antagonist. TR4 will be weighed into opaque capsules and released for individual patients, in accordance with good manufacturing practice (GMP).

Sponsors & Collaborators

  • Hammersmith Medicines Research

    collaborator OTHER

  • Trio Medicines Ltd.

    lead INDUSTRY

Principal Investigators

  • Denisa Wilkes · Hammersmith Medicines Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-28
Primary Completion
2022-08-16
Completion
2022-08-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07272135 on ClinicalTrials.gov